Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA

Overview

Journal Rheumatol Ther

Specialty Rehabilitation Medicine

Date 2019 Aug 7

PMID 31385264

Citations 34

Authors

Christine Radawski

Mark C Genovese

Brett Hauber

W Benjamin Nowell

Kelly Hollis

Carol L Gaich

Amy M DeLozier

Kelly Gavigan

Maria Reynolds

Anabela Cardoso

Jeffrey R Curtis

Affiliations

Soon will be listed here.

Abstract

Introduction: Many rheumatoid arthritis (RA) patients do not achieve their treatment goals and experience symptoms that affect psychosocial outcomes and daily activities. This study aimed to identify and quantify the unmet needs perceived by US patients with RA currently taking a disease-modifying antirheumatic drug (DMARD).

Methods: A cross-sectional, web-based survey was conducted with RA patients recruited through CreakyJoints, an online patient support community, and ArthritisPower, an online patient research registry, from December 2017 to January 2018. Participant patients were aged ≥ 21 years, failed ≥ 1 DMARDs, and were receiving their current DMARD(s) for ≥ 6 months; they answered 50 questions about treatment history, RA symptoms, and flares and completed the Rheumatoid Arthritis Impact of Disease (RAID) questionnaire and the Treatment Satisfaction Questionnaire for Medication (TSQM). Treatment satisfaction was defined by a TSQM global satisfaction score ≥ 80.

Results: Of 415 patients screened, 258 (62%) were eligible and completed the survey; 87% were women, and 87% white, with mean (SD) age of 54.5 (11.4) years. A total of 232 patients (90%) had current or past biologic DMARD (bDMARD) use, with 67% currently on a bDMARD, 65% on ≥ 1 conventional synthetic DMARD, and 40% on methotrexate. Forty-three percent of patients reported daily/almost daily use of prescription pain medications, and 44% reported a current flare. Mean (SD) TSQM scores were 59 [20] for effectiveness, 59 [26] for side effects, 72 [18] for convenience, and 65 [21] for global satisfaction. The mean (SD) RAID overall score was 5.1 (2.0) on a 0-10 scale. Only 26% (67 patients) were satisfied with their RA treatment. Patients not satisfied with treatment reported higher RAID scores overall and by domain, and approximately half reported a current flare.

Conclusions: Results from this real-world survey suggest that three-fourths of RA patients are not satisfied with treatments, which include bDMARDs. Patients continued to experience bothersome symptoms that impacted their daily activities and life. There remains a need for improved disease management among currently treated RA patients.

Funding: Eli Lilly and Company (Indianapolis, IN, USA).

Citing Articles

Patient perspectives on rheumatic and musculoskeletal diseases: insights from a large-scale survey.

Alnaqbi K, Alaswad M, Alasfour S Clin Rheumatol. 2025; .

PMID: 40047988 DOI: 10.1007/s10067-025-07388-x.

Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open-label, non-randomised trial of long-acting injectable buprenorphine treatment in Australian custodial settings.

White B, Little S, Haber P, Roberts J, Nolan E, Lintzeris N Drug Alcohol Rev. 2025; 44(2):640-648.

PMID: 39901317 PMC: 11814349. DOI: 10.1111/dar.14005.

Belonging, happiness, freedom and empowerment-a qualitative study of patients' understanding of health in early rheumatoid arthritis.

Landgren E, Mogard E, Bremander A, Lindqvist E, Nylander M, Larsson I BMC Rheumatol. 2024; 8(1):29.

PMID: 38937849 PMC: 11212251. DOI: 10.1186/s41927-024-00399-2.

Identification of Gaps in Quality of Care and Good Practice Interventions in Rheumatoid Arthritis: Insights From a Literature Review and Qualitative Study of Nine Centers in North America.

Curtis J, Bykerk V, Crow M, Danila M, Haraoui B, Karpouzas G ACR Open Rheumatol. 2024; 6(9):542-552.

PMID: 38937104 PMC: 11506565. DOI: 10.1002/acr2.11695.

Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab.

Tsumoto K, Takeuchi T BioDrugs. 2024; 38(3):341-351.

PMID: 38584236 PMC: 11055793. DOI: 10.1007/s40259-024-00648-3.

References

Smolen J, Breedveld F, Burmester G, Bykerk V, Dougados M, Emery P . Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2015; 75(1):3-15. PMC: 4717393. DOI: 10.1136/annrheumdis-2015-207524. View

Califf R . Benefit-Risk Assessments at the US Food and Drug Administration: Finding the Balance. JAMA. 2017; 317(7):693-694. DOI: 10.1001/jama.2017.0410. View

Fries J, Spitz P, Kraines R, HOLMAN H . Measurement of patient outcome in arthritis. Arthritis Rheum. 1980; 23(2):137-45. DOI: 10.1002/art.1780230202. View

Gossec L, Paternotte S, Aanerud G, Balanescu A, Boumpas D, Carmona L . Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis. 2011; 70(6):935-42. DOI: 10.1136/ard.2010.142901. View

Ometto F, Raffeiner B, Bernardi L, Bostsios C, Veronese N, Punzi L . Self-reported flares are predictors of radiographic progression in rheumatoid arthritis patients in 28-joint disease activity score remission: a 24-month observational study. Arthritis Res Ther. 2016; 18:89. PMC: 4831166. DOI: 10.1186/s13075-016-0986-1. View

Fraenkel L, Nowell W, Michel G, Wiedmeyer C . Preference phenotypes to facilitate shared decision-making in rheumatoid arthritis. Ann Rheum Dis. 2017; 77(5):678-683. PMC: 5898982. DOI: 10.1136/annrheumdis-2017-212407. View

Strand V, Wright G, Bergman M, Tambiah J, Taylor P . Patient Expectations and Perceptions of Goal-setting Strategies for Disease Management in Rheumatoid Arthritis. J Rheumatol. 2015; 42(11):2046-54. DOI: 10.3899/jrheum.140976. View

van den Reek J, van Luumig P, Otero M, Zweegers J, van de Kerkhof P, Ossenkoppele P . Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network. Br J Dermatol. 2014; 170(5):1158-65. DOI: 10.1111/bjd.12862. View

Taylor P, Moore A, Vasilescu R, Alvir J, Tarallo M . A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 2016; 36(5):685-95. PMC: 4839053. DOI: 10.1007/s00296-015-3415-x. View

10.

Kuettel D, Primdahl J, Christensen R, Ornbjerg L, Horslev-Petersen K . Impact of patient-reported flares on radiographic progression and functional impairment in patients with rheumatoid arthritis: a cohort study based on the AMBRA trial. Scand J Rheumatol. 2017; 47(2):87-94. DOI: 10.1080/03009742.2017.1329457. View

11.

Poulos C, Hauber A, Gonzalez J, Turpcu A . Patients' willingness to trade off between the duration and frequency of rheumatoid arthritis treatments. Arthritis Care Res (Hoboken). 2013; 66(7):1008-15. DOI: 10.1002/acr.22265. View

12.

Jenkins H, Spencer E, Weissgerber A, Osborne L, Pellegrini J . Correlating an 11-point verbal numeric rating scale to a 4-point verbal rating scale in the measurement of pruritus. J Perianesth Nurs. 2009; 24(3):152-5. DOI: 10.1016/j.jopan.2009.01.010. View

13.

Kaufmann J, Feist E, Roske A, Schmidt W . Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin Rheumatol. 2013; 32(9):1347-55. DOI: 10.1007/s10067-013-2281-8. View

14.

Atkinson M, Kumar R, Cappelleri J, Hass S . Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health. 2005; 8 Suppl 1:S9-S24. DOI: 10.1111/j.1524-4733.2005.00066.x. View

15.

Dougados M, Brault Y, Logeart I, van der Heijde D, Gossec L, Kvien T . Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID). Arthritis Res Ther. 2012; 14(3):R129. PMC: 3446510. DOI: 10.1186/ar3859. View

16.

Funahashi K, Matsubara T . What RA patients expect of their treatment--discussion over the result of our survey. Clin Rheumatol. 2012; 31(11):1559-66. DOI: 10.1007/s10067-012-2048-7. View

17.

Atkinson M, Sinha A, Hass S, Colman S, Kumar R, Brod M . Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004; 2:12. PMC: 398419. DOI: 10.1186/1477-7525-2-12. View

18.

Takahashi N, Sasaki K, Nishiyama T, Naniwa T . Satisfaction and attitudes toward therapy in patients with rheumatoid arthritis. Mod Rheumatol. 2011; 22(3):376-81. DOI: 10.1007/s10165-011-0531-7. View

19.

Van der Elst K, Verschueren P, Stouten V, Pazmino S, De Groef A, De Cock D . Patient-Reported Outcome Data From an Early Rheumatoid Arthritis Trial: Opportunities for Broadening the Scope of Treating to Target. Arthritis Care Res (Hoboken). 2019; 71(12):1566-1575. DOI: 10.1002/acr.23900. View

20.

Salaffi F, Di Carlo M, Vojinovic J, Tincani A, Sulli A, Soldano S . Validity of the rheumatoid arthritis impact of disease (RAID) score and definition of cut-off points for disease activity states in a population-based European cohort of patients with rheumatoid arthritis. Joint Bone Spine. 2017; 85(3):317-322. DOI: 10.1016/j.jbspin.2017.05.020. View